The combination of nivolumab and relatimab (anti-LAG3 antibody; lymphocyte activation gene 3 is expressed in NK cells, B cells, and activated T cells and limits their proliferation and activation) is currently being evaluated in patients with unresectable or metastatic uveal melanomas (NCT03743766) [76]. This evidence concerns the gene LAG3 and uveal melanoma.